Cencora's Stock Soars: Strong Q3 Results & Bullish Outlook

Cencora, a pharmaceutical services giant valued at nearly $59 billion, is making waves in the healthcare supply chain. Despite a minor dip, its stock (COR) has surged by 18.9% over the last three months, outperforming the broader Health Care Select Sector SPDR Fund. Year-to-date, Cencoras shares have risen by 56.1%, and theyve been trading above their moving averages since early January. The companys strong third-quarter results, with a 5.9% year-over-year revenue increase and a 15% adjusted earnings per share growth, further boosted its stock. Wall Street analysts are bullish, with a consensus price target suggesting a potential 10.5% upside.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.